These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 7997767)
21. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470 [TBL] [Abstract][Full Text] [Related]
22. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)]. Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998 [No Abstract] [Full Text] [Related]
23. Drug hypersensitivity syndrome induced by meglumine antimoniate. Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092 [TBL] [Abstract][Full Text] [Related]
25. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536 [TBL] [Abstract][Full Text] [Related]
26. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis. Berhe N; Abraham Y; Hailu A; Ali A; Mengistu G; Tsige K; Abebe Y East Afr Med J; 2001 Nov; 78(11):608-10. PubMed ID: 12219968 [TBL] [Abstract][Full Text] [Related]
27. Combination therapy with liposomal amphotericin b (ambisome), n-methylglucamine antimoniate (glucantime), and pentamidine isethionate in a refractory visceral leishmaniasis case. Gomes MAF; Medeiros LLC; Lobo FPD; Wanderley NRS; Matos APR; Jácome TDN; Monteiro MGL; Luz KG Rev Soc Bras Med Trop; 2018; 51(3):393-396. PubMed ID: 29972577 [TBL] [Abstract][Full Text] [Related]
28. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil. Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762 [TBL] [Abstract][Full Text] [Related]
29. [N-methyl glucamine antimoniate or Glucantime]. Rapp C; Simon F; Dordain ML Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584 [No Abstract] [Full Text] [Related]
30. Pentavalent antimonial-induced torsade de pointes. Ortega-Carnicer J; Alcázar R; De la Torre M; Benezet J J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610 [TBL] [Abstract][Full Text] [Related]
31. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil. Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324 [TBL] [Abstract][Full Text] [Related]
32. Meglumine antimoniate-induced pancreatitis. Torrús D; Massa B; Boix V; Portilla J; Pérez-Mateo M Am J Gastroenterol; 1996 Apr; 91(4):820-1. PubMed ID: 8677970 [No Abstract] [Full Text] [Related]
33. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Gasser RA; Magill AJ; Oster CN; Franke ED; Grögl M; Berman JD Clin Infect Dis; 1994 Jan; 18(1):83-90. PubMed ID: 7519887 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate. Schettini DA; Costa Val AP; Souza LF; Demicheli C; Rocha OG; Melo MN; Michalick MS; Frézard F Braz J Med Biol Res; 2005 Dec; 38(12):1879-83. PubMed ID: 16302103 [TBL] [Abstract][Full Text] [Related]
36. An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable. de Oliveira-Neto MP; Mattos Mda S Rev Soc Bras Med Trop; 2006; 39(4):323-6. PubMed ID: 17119744 [TBL] [Abstract][Full Text] [Related]
37. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate. Aste N; Pau M; Ferreli C; Biggio P Br J Dermatol; 1998 Feb; 138(2):370-1. PubMed ID: 9602904 [No Abstract] [Full Text] [Related]